Sana Biotechnology Inc
NASDAQ:SANA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.645
11.27
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SANA stock under the Base Case scenario is 0.922 USD. Compared to the current market price of 2.645 USD, Sana Biotechnology Inc is Overvalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sana Biotechnology Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SANA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Sana Biotechnology Inc
Balance Sheet Decomposition
Sana Biotechnology Inc
Current Assets | 263.5m |
Cash & Short-Term Investments | 251.6m |
Other Current Assets | 11.8m |
Non-Current Assets | 355.2m |
PP&E | 149.1m |
Intangibles | 199.8m |
Other Non-Current Assets | 6.3m |
Current Liabilities | 50.7m |
Accounts Payable | 3.8m |
Accrued Liabilities | 44.8m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 228.3m |
Other Non-Current Liabilities | 228.3m |
Earnings Waterfall
Sana Biotechnology Inc
Revenue
|
0
USD
|
Operating Expenses
|
-252.9m
USD
|
Operating Income
|
-252.9m
USD
|
Other Expenses
|
8m
USD
|
Net Income
|
-244.9m
USD
|
Free Cash Flow Analysis
Sana Biotechnology Inc
USD | |
Free Cash Flow | USD |
SANA Profitability Score
Profitability Due Diligence
Sana Biotechnology Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Sana Biotechnology Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
SANA Solvency Score
Solvency Due Diligence
Sana Biotechnology Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Sana Biotechnology Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SANA Price Targets Summary
Sana Biotechnology Inc
According to Wall Street analysts, the average 1-year price target for SANA is 13.668 USD with a low forecast of 11.11 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for SANA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SANA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 383 full-time employees. The company went IPO on 2021-02-04. The firm is focused on creating and delivering engineered cells as medicines for patients. The firm develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).
Contact
IPO
Employees
Officers
The intrinsic value of one SANA stock under the Base Case scenario is 0.922 USD.
Compared to the current market price of 2.645 USD, Sana Biotechnology Inc is Overvalued by 65%.